Viridian Therapeutics, Inc.
Framing the future of autoimmune diseases
Waltham, United States
163 employees
Post-IPO Equity
Total: $681.70M
Biotechnology, Health Care +1
General Information
Waltham, United States
BounceWatch is an independent company data service, not affiliated with Viridian Therapeutics, Inc.. To contact Viridian Therapeutics, Inc., visit viridiantherapeutics.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
United States Market
Biotechnology
About Viridian Therapeutics, Inc.
Taxonomy: medicine, pharmaceuticals, clinical-stage, monoclonal antibody, thyroid eye disease, disease treatment, IGF-1R, Waltham, Massachusetts, startup, investor
Funding Rounds & Investors (13)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $150.00M | - |
|
17 Jan 2024 |
| Post IPO Equity | $185.00M | - |
|
30 Oct 2023 |
| Post IPO Debt | $75.00M | 1 |
|
04 Apr 2022 |
| Post IPO Equity | $85.00M | - |
|
21 Sep 2021 |
| Post IPO Equity | $91.00M | - |
|
06 Nov 2020 |
| Post IPO Equity | $1.50M | - |
|
06 Aug 2018 |
| Series C | $40.70M | 8 |
|
10 Nov 2015 |
| Series B | $8.50M | 5 |
|
18 Feb 2015 |
| Series B | $7.00M | 5 |
|
27 Jun 2014 |
| Series B | $20.00M | 5 |
|
24 Apr 2012 |
Viridian Therapeutics, Inc. Alternatives & Competitors
View All Alternatives
Building a future where the immune system stands strong against cancer and critical diseases with in...
Building a leading biotech company focused in severe autoimmune diseases.
Advancing peptides for the treatment of rare endocrine and related diseases
FAQ About Viridian Therapeutics, Inc.
Source: BounceWatch company record for Viridian Therapeutics, Inc., https://bouncewatch.com/company/viridian-therapeutics-inc, updated 28 November 2024. When citing, please name BounceWatch and link this page.
